Business
Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury
- Clinical Trial Application (CTA) submitted in the United Kingdom for first in human study of TD-0903, an investigational lung-selective nebulized JAKi with
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"- Clinical Trial Application (CTA) submitted in the United Kingdom for first in human study of TD-0903, an investigational lung-selective nebulized JAKi with potential to treat Acute Lung Injury caused by COVID-19\n - Near-term clinical development program enables progression from healthy volunteers to hospitalized COVID-19 patients\n\n\nDUBLIN and SOUTH SAN FRANCISCO, Calif., April 9, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (\"Theravance Biopharma\" or the \"Company\"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with Acute Lung Injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to Acute Respiratory Distress Syndrome (ARDS). \n\n \n \n \n \n \n \n\n \n\"In response to the unprecedented healthcare challenges presented by the emergence of COVID-19, we have combined our immunology and respiratory medicine expertise to accelerate development of our nebulized lung-selective JAK inhibitor, TD-0903. With great urgency, we have redirected our program to treat the acute lung injury caused by COVID-19,\" said Rick E Winningham, Chief Executive Officer. \"We recognize how critical it is to help those suffering from shortness of breath and low oxygen levels, including those who need intensive care and ventilation, to address the effects of profound lung hyperinflammation. TD-0903 could provide benefit to hospitalized patients by preventing the progression of lung hyperinflammation and reducing the requirement for, or the duration of, assisted ventilation. As a result, this could improve utilization of limited hospital critical care resources.\"\n\"We are pleased to be able to direct our resources and expertise towards helping to treat COVID-19,\" said Brett Haumann, M.D. Chief Medical Officer. \"Janus kinase inhibitors have the potential to inhibit a broad set of immune-modulatory pathways that could prove to be effective in dampening the abnormal immune response that occurs in the lungs of some patients. The nebulized formulation of our lung-selective inhaled JAK inhibitor will ...